CO6670575A2 - Aminopirazoloqinazolinas sustituidas, útiles en el tratamiento de enfermedades proliferativas y composiciones farmaceúticas que las continen - Google Patents

Aminopirazoloqinazolinas sustituidas, útiles en el tratamiento de enfermedades proliferativas y composiciones farmaceúticas que las continen

Info

Publication number
CO6670575A2
CO6670575A2 CO13011464A CO13011464A CO6670575A2 CO 6670575 A2 CO6670575 A2 CO 6670575A2 CO 13011464 A CO13011464 A CO 13011464A CO 13011464 A CO13011464 A CO 13011464A CO 6670575 A2 CO6670575 A2 CO 6670575A2
Authority
CO
Colombia
Prior art keywords
treatment
aminopyrazoloqinazolines
continue
substituted
useful
Prior art date
Application number
CO13011464A
Other languages
English (en)
Spanish (es)
Inventor
Matthias Treu
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43037625&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6670575(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of CO6670575A2 publication Critical patent/CO6670575A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/12Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
    • C07D493/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CO13011464A 2010-07-23 2013-01-22 Aminopirazoloqinazolinas sustituidas, útiles en el tratamiento de enfermedades proliferativas y composiciones farmaceúticas que las continen CO6670575A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10170683 2010-07-23

Publications (1)

Publication Number Publication Date
CO6670575A2 true CO6670575A2 (es) 2013-05-15

Family

ID=43037625

Family Applications (1)

Application Number Title Priority Date Filing Date
CO13011464A CO6670575A2 (es) 2010-07-23 2013-01-22 Aminopirazoloqinazolinas sustituidas, útiles en el tratamiento de enfermedades proliferativas y composiciones farmaceúticas que las continen

Country Status (23)

Country Link
US (1) US8735386B2 (https=)
EP (1) EP2595987B1 (https=)
JP (1) JP5991974B2 (https=)
KR (1) KR20130132394A (https=)
CN (1) CN103097388A (https=)
AP (1) AP2012006640A0 (https=)
AR (1) AR082850A1 (https=)
AU (1) AU2011281504A1 (https=)
BR (1) BR112013000107A2 (https=)
CA (1) CA2803467A1 (https=)
CL (1) CL2012003745A1 (https=)
CO (1) CO6670575A2 (https=)
EA (1) EA201201661A1 (https=)
EC (1) ECSP13012448A (https=)
GE (1) GEP20156289B (https=)
MA (1) MA34389B1 (https=)
MX (1) MX2013000821A (https=)
PE (1) PE20131143A1 (https=)
PH (1) PH12013500152A1 (https=)
SG (1) SG187548A1 (https=)
TW (1) TW201217380A (https=)
UY (1) UY33526A (https=)
WO (1) WO2012010704A1 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013110585A1 (en) 2012-01-23 2013-08-01 Boehringer Ingelheim International Gmbh 5, 8 -dihydro- 6h- pyrazolo [3, 4 -h] quinazolines as igf-lr/lr inhibitors
US9376437B2 (en) 2013-03-13 2016-06-28 Oncoceutics, Inc 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy
KR102318238B1 (ko) * 2013-11-15 2021-10-26 온코슈틱스 인코포레이티드 7-벤질-4-(2-메틸벤질)-2,4,6,7,8,9-헥사하이드로이미다조[1,2-a]피리도[3,4-e]피리미딘-5(1H)-온, 이의 염 및 이의 용도
HUE052821T2 (hu) 2015-01-30 2021-05-28 Oncoceutics Inc 7-benzil-4-(4-trifluormetil)benzil-1,2,6,7,8,9-hexahidroimidazo[1,2-a]pirido[3,4-e]pirimidin-5(4H)-on és sói és azok terápiában történõ alkalmazása
JP6664414B2 (ja) * 2015-05-13 2020-03-13 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング IGF−1R/IR阻害薬としての新規5,8−ジメチル−9−フェニル−5,8−ジヒドロ−6H−ピラゾロ[3,4−h]キナゾリン−2−イル)−(1H−ピラゾール−3−イル)−アミン及び誘導体
EP3505519B1 (en) * 2016-11-11 2022-01-05 Shanghai Haiyan Pharmaceutical Technology Co., Ltd. Pyridinamine-substituted heterotricyclo compounds, preparation thereof, and use in medicines
EP3632904B1 (en) * 2017-05-26 2022-04-20 Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd. Urat1 inhibitors for promoting uric acid excretion
CN107383019B (zh) * 2017-07-28 2019-10-15 江苏艾凡生物医药有限公司 吡唑并[4,3-h]喹唑啉类化合物及其用途
WO2019206154A1 (zh) 2018-04-24 2019-10-31 上海海雁医药科技有限公司 Cdk4/6抑制剂及其药学上可接受的盐和多晶型物及其应用
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
SG11202109443QA (en) 2018-11-02 2021-09-29 Fount Bio Inc Crosslinked materials
US12570670B2 (en) 2019-01-30 2026-03-10 Yale University Compounds, compositions, and methods for treating fibrosis
US11384083B2 (en) 2019-02-15 2022-07-12 Incyte Corporation Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
TW202100520A (zh) 2019-03-05 2021-01-01 美商英塞特公司 作為cdk2 抑制劑之吡唑基嘧啶基胺化合物
BR112021016960A2 (pt) * 2019-03-07 2021-11-23 BioNTech SE Processo para a preparação de uma imidazoquinolina substituída
WO2020205560A1 (en) 2019-03-29 2020-10-08 Incyte Corporation Sulfonylamide compounds as cdk2 inhibitors
US20220175819A1 (en) * 2019-04-19 2022-06-09 Fount Bio, Inc. Delivery and retention of active agents within the skin
WO2020223469A1 (en) 2019-05-01 2020-11-05 Incyte Corporation N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
CA3150681A1 (en) 2019-08-14 2021-02-18 Incyte Corporation Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors
US11851426B2 (en) 2019-10-11 2023-12-26 Incyte Corporation Bicyclic amines as CDK2 inhibitors
US11345681B1 (en) 2020-06-05 2022-05-31 Kinnate Biopharma Inc. Inhibitors of fibroblast growth factor receptor kinases
CN111960974A (zh) * 2020-08-28 2020-11-20 山东潍坊润丰化工股份有限公司 一种烯草酮中间体的合成方法
CN121537408A (zh) 2021-02-08 2026-02-17 上海复星医药产业发展有限公司 5,6-二氢噻吩并[3,4-h]喹唑啉类化合物
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3071830B2 (ja) * 1995-10-02 2000-07-31 エフ・ホフマン−ラ ロシュ アーゲー 5ht2c受容体アンタゴニストとしてのピリミジン誘導体
BR122019010200B8 (pt) 2003-05-22 2021-07-27 Nerviano Medical Science S R L compostos de pirazol-quinazolina, seus sais, produtos ou kits e composições farmacêuticas
CN1897950A (zh) 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法

Also Published As

Publication number Publication date
UY33526A (es) 2012-02-29
EA201201661A1 (ru) 2013-07-30
CN103097388A (zh) 2013-05-08
GEP20156289B (en) 2015-05-25
JP2013532652A (ja) 2013-08-19
KR20130132394A (ko) 2013-12-04
CL2012003745A1 (es) 2013-05-31
MA34389B1 (fr) 2013-07-03
CA2803467A1 (en) 2012-01-26
EP2595987A1 (en) 2013-05-29
US20120238542A1 (en) 2012-09-20
PH12013500152A1 (en) 2013-02-18
SG187548A1 (en) 2013-03-28
AR082850A1 (es) 2013-01-16
AP2012006640A0 (en) 2012-12-31
WO2012010704A1 (en) 2012-01-26
ECSP13012448A (es) 2013-03-28
AU2011281504A1 (en) 2013-01-10
PE20131143A1 (es) 2013-10-23
US8735386B2 (en) 2014-05-27
BR112013000107A2 (pt) 2016-05-17
MX2013000821A (es) 2013-05-30
TW201217380A (en) 2012-05-01
JP5991974B2 (ja) 2016-09-14
EP2595987B1 (en) 2018-04-18

Similar Documents

Publication Publication Date Title
CO6670575A2 (es) Aminopirazoloqinazolinas sustituidas, útiles en el tratamiento de enfermedades proliferativas y composiciones farmaceúticas que las continen
UY33817A (es) ?nuevas oxindolpirimidinas bencílicas?.
PE20151023A1 (es) Triazolopirazinas
UY33199A (es) 5-alquinil-pirimidinas.
UY35827A (es) Derivados de triazolopirazina como inhibidores de la proteína brd4
UY32259A (es) Nuevos compuestos de hidroxiareno, preparados farmaceuticos que los contienen y aplicaciones
UY33890A (es) Nuevas azaindolilfenil sulfonamidas como inhibidores de serina/ treonina cinasa
GT201400063A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
UY32916A (es) Nuevas pirimidinas, sus sales farmacéuticamente aceptables, composiciones conteniéndolas y aplicaciones
UY32673A (es) Nuevas pirimidinas, composiciones farmaceuticas que las contienen, procedimientos de preparaciones y su aplicacion como medicamentos
UY31198A1 (es) Amidas de ácidos benzoicos triazinil sustituidos, composiciones farmacéticas conteniéndolos y aplicaciones.
MX2016014547A (es) Compuestos para tratar atrofia muscular espinal.
CY1118859T1 (el) 6-αλκινυλο-πυριδινες ως μιμητες smac
UY32494A (es) Nuevas 2,4-diaminopirimidinas, sales farmacéuticas de las mismas, composiciones conteniéndolas y aplicaciones
UY32240A (es) Nuevas 2,4-diaminopirimidinas, sus sales farmacéuticamente aceptables, composiciones conteniéndolas y aplicaciones.
UY34955A (es) 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos
UY33349A (es) Nuevos compuestos de quinoxalina, quinolina y quinazolina, composiciones farmacéuticas que los contienen y uso de los mismos
CO2017007325A2 (es) 2,4 diamino-quinolina sustituida como nuevos agentes anti-cancerigenos
ECSP11011454A (es) 5-alquinil-piridinas
ECSP12012110A (es) 5-alquinil-pirimidinas
MX2015008036A (es) Compuestos antibacterianos.
ECSP11011464A (es) Tia-triaza-ciclopentazulenos
UY33214A (es) Compuestos de aril-bencil-amina
UY33816A (es) ?nuevas triazolilfenil sulfonamidas como inhibidores de serina/treonina cinasa?.
ECSP12012115A (es) 5-alquinil-pirimidinas

Legal Events

Date Code Title Description
FG Application granted